Retinoids Augment the Expression of Podocyte Proteins by Glomerular Parietal Epithelial Cells in Experimental Glomerular DiseaseZhang J.a · Pippin J.W.a · Vaughan M.R.a · Krofft R.D.a · Taniguchi Y.a · Romagnani P.b · Nelson P.J.a · Liu Z.-H.c · Shankland S.J.a
aDivision of Nephrology, Department of Medicine, University of Washington School of Medicine, Seattle, Wash., USA; bExcellence Center for Research, Transfer and High Education Denothe, University of Florence, Florence, Italy; cResearch Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Corresponding Author
Stuart J. Shankland
Department of Medicine, Division of Nephrology
University of Washington School of Medicine, Box 356521
BB-1265 H.S.B., 1959 NE Pacific Street, Seattle, WA 98195-6521 (USA)
Background/Aims: A decrease in glomerular podocyte number in membranous nephropathy and focal segmental glomerulosclerosis (FSGS) ultimately underlines glomerulosclerosis and the decrease in kidney function. Recent studies have shown that in these diseases, glomerular parietal epithelial cells begin to express proteins considered unique to podocytes, and that these glomerular epithelial transition cells might serve as podocyte progenitors. Because retinoids improve many forms of experimental glomerular disease characterized by podocyte injury and loss, we asked if all-trans retinoic acid (ATRA) induces parietal epithelial cells to express podocyte proteins. Methods: ATRA or vehicle was administered to rats with experimental membranous nephropathy (passive Heymann nephritis model) and mice with experimental FSGS (anti-glomerular antibody model) following the onset of proteinuria. Immunohistochemistry staining of PAX2 (parietal epithelial cell marker), WT-1 (podocyte cell marker), and Ki-67 (proliferation marker) were performed on kidney tissues. Results: Compared to diseased animals receiving vehicle, ATRA statistically significantly increased the number of glomerular transition cells, defined as cells double-staining for PAX2 and WT-1, in membranous nephropathy at weeks 2, 5 and 16, and in FSGS at weeks 1 and 2. This was accompanied by an increase in the number of podocytes compared to diseased controls receiving vehicle. Conclusion: ATRA increases the number of glomerular epithelial transition cells in experimental proteinuric glomerular diseases. Thus, ATRA may provide a useful pharmacologic approach to decipher the mechanisms underlying the possible progenitor role of parietal epithelial cells.
© 2012 S. Karger AG, Basel
Podocytes are terminally differentiated glomerular epithelial cells, and therefore are unable to proliferate adequately to replace those lost in several glomerular diseases . Reduced podocyte number directly underlies the development of proteinuria and progressive glomerulosclerosis [2,3]. Several recent lines of evidence suggest that glomerular parietal epithelial cells (PECs) may serve as progenitor cells for podocytes, as a possible repair mechanism to replace any decrease in podocyte number. Appel et al.  used a PEC-specific reporter mouse to show that PECs give rise to podocytes in immature mice. Sagrinati et al.  and Ronconi et al.  showed that normal PECs express progenitor markers, and using a cell therapy approach, showed improved disease outcomes in an experimental mouse model. We, and others, have shown in certain experimental glomerular diseases and in aging nephropathy that PECs begin to express proteins considered specific for podocytes such as WT-1 and synaptopodin [7,8]. Some have called these glomerular epithelial transitional cells, although there are no reports yet showing that this subpopulation of PECs become functional podocytes.
To our knowledge, the mechanisms underlying how PECs begin to express podocyte proteins are not well understood, nor do we understand how the number of cells doing so increase. While several candidates are likely, we focused our current studies on the vitamin A derivative all-trans retinoic acid (ATRA) for the following reasons. First, ATRA is a potent inducer of differentiation in certain non-renal epithelial cells [9,10,11]. Second, Ronconi et al.  used ATRA in the cell culture media to promote PEC differentiation towards the podocyte lineage. Third, we and others have shown that ATRA enhances podocyte recovery in disease, although the mechanisms are not well delineated [12,13,14,15,16]. Finally, ATRA also enhances podocyte differentiation in cultured cells [3,13].
The purpose of this study was to determine if ATRA increased the number of glomerular epithelial transition cells (defined as cells expressing a PEC and a podocyte protein) in two models of experimental glomerular disease characterized by reduced podocyte number.
Passive Heymann Nephritis Model of Experimental Membranous Nephropathy
The passive Heymann nephritis (PHN) model of membranous nephropathy has been well characterized by our group and others [17,18]. The study was designed to answer two questions (fig. 1A): First, does ATRA impact the number of glomerular transition cells in disease? Second, if so, was this impacted by the timing of when ATRA was first administered (i.e. early vs. late in the course of disease)?
PHN was induced in male Sprague-Dawley rats (Charles River), weighing 300–350 g, with intraperitoneal injection of sheep anti-rat tubular fraction 1a (Fx1a) antibody (1 ml/200 g BW) as previously described . Rats were housed in the animal care facility of the University of Washington under standardized pathogen-free conditions (25°C, 50% humidity, 12:12-hour light-dark cycle) with food and water available ad libitum. Urinary protein was measured (see method below) on all rats at day 5, the time by when proteinuria has typically developed. Rats were excluded from the study if they did not develop proteinuria by day 5. A total of 22 age- and weight-matched PHN rats were included. Of these proteinuric PHN rats, rats were randomly assigned as follows: 17 were given the vehicle DMSO (5 times weekly intraperitoneal injection of DMSO 15 mg/kg); 5 PHN rats were randomly assigned to start immediately on ATRA (5 times weekly intraperitoneal injection of ATRA 16.6 mg/kg) to determine if the early onset of ATRA treatment had an effect on glomerular epithelial transition cells. These animals are referred to as ‘early treated’ rats. All 5 ATRA-treated PHN rats underwent a survival biopsy after 7 days of treatment, and all were sacrificed at 5 weeks. Of the DMSO-treated PHN group, 5 were randomly assigned to undergo a survival biopsy  1 week after DMSO initiation. These rats were continued on DMSO until week 5 at which time they were sacrificed.
Thus, by week 5, twelve DMSO-treated PHN rats remained in the study. To determine the impact of beginning ATRA therapy at this later stage of advanced disease, 6 of these DMSO-treated PHN rats were randomly assigned to receive ATRA (5 times first week and 3 times weekly followed by intraperitoneal injection of ATRA 5 mg/kg), and 6 to remain on DMSO for a total of another 10 weeks. The ‘late-treatment’ animals were sacrificed at week 16.
Because of concerns regarding the half-life of ATRA, ‘fresh’ ATRA was reconstituted on the day of each injection, and ATRA was given repeatedly throughout the week.
Although the primary purpose of this study was to determine if ATRA altered the number of glomerular epithelial transition cells in PHN rats compared to a disease group receiving the vehicle DMSO, two additional groups of nondiseased control rats were included as follows. In order to have baseline data to compare the effect of DMSO on disease outcomes, 11 age-matched Sprague-Dawley male rats received normal sheep serum (used as a control for the sheep Fx1a antibody). Of these, 6 normal sheep serum-injected control rats were randomly sacrificed at week 1, coinciding with the initiation of early treatment of ATRA or DMSO to PHN rats. They served as the control baseline for the early-treatment rats. Because of the potential concern regarding the effect of age and weight changing on outcomes, the remaining 5 normal sheep serum-injected controls were sacrificed at week 16, and served as controls for the late-treatment rats.
Mouse Model of Experimental Focal Segmental Glomerulosclerosis (fig. 1B)
We have previously reported that giving mice the sheep anti-glomerular antibody used in this study (αglom) leads to features consistent with classic focal segmental glomerulosclerosis (FSGS), namely reduced podocyte number, focal glomerulosclerosis and proteinuria . Accordingly, C57BL6 mice were given sheep anti-glomerular antibody (0.3 ml/20 g BW, for 2 consecutive days)  to induce experimental FSGS. On day 3 of disease, 10 age- and weight-matched mice were randomly assigned to receive either ATRA (daily intraperitoneal injection of ATRA 16.6 mg/kg), and the remaining 10 diseased mice were randomly assigned to received vehicle (corn oil, 30–60 µl). On day 7 of disease, 5 animals from the ATRA group and 5 from the vehicle group were randomly selected for urine measurement, and then sacrificed. The remaining 5 animals in each group continued to receive either ATRA or vehicle. On day 14, urine was collected from all, followed by sacrifice. These kidney samples are from our previously published data . Although the primary purpose of the study was to compare ATRA versus vehicle in FSGS mice, a group of nondiseased control mice received normal sheep serum (n = 5) to serve as a baseline for comparison for the vehicle-treated disease group. These animals were also sacrificed at day 7.
Rats were placed into individual metabolic cages overnight and spontaneously voided urine was collected for 12 h prior to disease induction, on day 5 prior to ATRA or DMSO administration, and at each time prior to survival biopsy or sacrifice. Urine protein was determined using the sulfosalicylic acid method  and urine creatinine was determined using a colorimetric microplate assay (Oxford Biomedical Research, Oxford, Mich., USA and Cayman Chemical Co., Ann Arbor, Mich., USA), as we have previously reported .
Double Immunohistochemistry Staining Methods
To identify and quantitate the number of glomerular epithelial cells that express both podocyte and PEC proteins (defined as glomerular transition epithelial cells), double staining was performed. Indirect immunoperoxidase staining was performed on 4-µm-thick section kidney biopsies fixed in formalin and embedded in paraffin as we have previously reported . In brief, paraffin was removed using Histoclear (National Diagnostics, Atlanta, Ga., USA), and sections were rehydrated in ethanol. Antigen retrieval was performed by boiling sections in the microwave in 1 mm EDTA, pH 6.0. Endogenous peroxidase activity was quenched with alkaline phosphatase/horseradish peroxidase block (BioFX Laboratories, Owings Mills, Md., USA). Nonspecific protein binding was blocked with background buster (Accurate Chemical & Scientific, Westbury, N.Y., USA). After the blocking steps described above, tissue sections were incubated overnight at 4°C with the primary antibodies. The following primary antibodies were used: rabbit anti-rat paired box gene 2 (PAX2, PEC nuclear protein) polyclonal antibody (Zymed Laboratories, South San Francisco, Calif., USA) and rabbit anti-WT-1 (WT-1, podocyte nuclear protein) polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, Calif., USA).
Staining with antibody to PAX2 was performed first. The method for PAX2 staining was identical to the single staining methods we reported previously , and was visualized with the Vector SG substrate kit, with positive cells being a bluish-gray color (Vector). Following SG substrate color development blocking steps were performed. Because both of the antibodies being used were developed in rabbits, an anti-rabbit IgG antibody Fab fragment (Jackson ImmunoResearch, West Grove, Pa., USA) was used to saturate all the binding sites created during the first set of staining. In addition, peroxidase activity derived from the first set of staining was also blocked using alkaline phosphatase/horseradish peroxidase block (BioFX Laboratories). Next, a second set of staining was performed for WT-1. A rabbit-on-rodent AP-polymer kit (Biocare Medical) was used for additional blocking and substitutive secondary antibody according to the manufacturer’s protocol. Staining was visualized with the Warp Red chromogen kit, red color (Biocare Medical).
To quantitate changes in podocyte number and cell proliferation in rats and mice given ATRA or vehicle, rabbit anti-WT-1 polyclonal antibody (Santa Cruz Biotechnology ) and rabbit anti-Ki-67 monoclonal antibody (Thermo Fisher Scientific, Fremont, Calif., USA) were used to identify podocyte cells and proliferating cells separately.
For WT-1 single staining, a rabbit-on-rodent AP-polymer kit (Biocare Medical) was used for additional blocking and substitutive secondary antibody according to the manufacturer’s protocol. Staining was visualized with the Warp Red chromogen kit, giving a red color (Biocare Medical).
For Ki-67 staining, a rabbit-on-rodent HRP-polymer kit (Biocare Medical) was used for additional blocking and substitutive secondary antibody according to the manufacturer’s protocol. Staining was visualized with the Vector SG substrate kit giving a blue gray color (Vector). Following SG substrate color development, PAS staining was performed by incubating the tissue in 0.5% periodic acid and Schiff’s reagent for 2 min separately, and then in 1% sodium metbisulfite solution for 10 min.
For nephrin and podocin staining, sections were incubated overnight at 4°C with guinea pig anti-nephrin antibody (Fitzgerald Industries, Concord, Mass., USA) or rabbit anti-podocin antibody (Alpha Diagnostics, San Antonio, Tex., USA) followed by biotinylated secondary antibodies (Vector). The ABC kit (Vector) was used for signal amplification and 3,3′-diaminobenzamidine (Sigma) was used as a chromogen. Quantification of nephrin and podocin staining was performed by examining all tissue sections for the intensity of glomerular staining as we have previously reported .
For all stains, negative controls consisted of omitting the primary antibodies. Normal rat and mouse kidneys were used as positive controls, as all the antigens are expressed under physiological conditions.
Quantification of positively stained cells was performed on individual animals at each time point using a combination of bright-field and fluorescent microscopy as we have reported . Double-positive cells were identified as follows. The presence of blue/gray color in the nucleus by bright-field microscopy indicated positive staining for PAX2. If the same nucleus also showed the presence of red color in the nucleus by fluorescent microscopy, this indicated positive staining for WT-1, and the cell was then considered a double-positive stained cell. The mean number of glomeruli analyzed was 30 (95% CI: 18–41) per animal. Because of known changes in glomerular size with aging and weight increasing, ImageJ software was used to measure the length of the Bowman’s basement membrane and glomerular tuft area according to ‘The ImageJ User Guide’ (version 1.44) as we described previously . These measures were then used as denominators for the number of positively stained podocytes, and double-stained cells along Bowman’s basement membrane and in tuft, respectively. For multiple comparisons, one-way ANOVA was used and post hoc analyses were performed by LSD test. Paired-samples t test was performed if animal number was equal in each group, which needs to compare; p < 0.05 was considered significant. All values are expressed as mean ± SEM.
To determine if ATRA increased the number of glomerular epithelial transition cells (defined as cells in the glomerulus expressing both PEC- and podocyte-specific proteins), double immunostaining was performed for PAX2 and WT-1 (fig. 2) in the early- and late-treatment PHN groups. The length of Bowman’s basement membrane, measured in millimeters, was used as the denominator.
The number of double-positive cells along Bowman’s basement membrane increased in the early DMSO treatment PHN rats at week 2 (3.98 ± 0.50 vs. 0.39 ± 0.17/mm Bowman’s basement membrane length, normal sheep serum-injected rats, p < 0.001) and week 5 (5.52 ± 0.63 vs. 0.39 ± 0.17/mm, normal sheep serum-injected rats, p < 0.001). Compared to DMSO treatment, the early treatment with ATRA significantly augmented the increase in the number of transitional cells lining Bowman’s basement membrane at week 2 (9.14 ± 0.50 vs. 3.98 ± 0.50/mm, DMSO-treated PHN rats, p < 0.001) and week 5 (8.74 ± 0.85 vs. 5.52 ± 0.63/mm, DMSO-treated PHN rats p < 0.001) (fig. 2E-1).
The number of transition cells within the glomerular tuft was also quantified, and was expressed as the number of cells double-staining for PAX2 and WT-1 per square millimeter of glomerular tuft area. Transition cells were not increased in the early DMSO-treated PHN rats at week 2 (26.43 ± 7.89 vs. 13.91 ± 7.97/mm2 glomerular tuft area, normal sheep serum-injected rats, p > 0.05), nor at week 5 (75.19 ± 16.72 vs. 13.91 ± 7.97/mm2, normal sheep serum-injected rats, p > 0.05). In contrast, in PHN rats, ATRA increased the number of transition cells per square millimeter of glomerular tuft area at week 2 (185.40 ± 16.79 vs. 26.43 ± 7.89/mm2, DMSO-treated PHN rats, p < 0.001) and week 5 (366.96 ± 62.80 vs. 75.19 ± 16.72/mm2, DMSO-treated PHN rats, p < 0.001) (fig. 2E-2).
These data show that when ATRA is first given to PHN rats at the onset of proteinuria, the number of glomerular transition cells is significantly increased along Bowman’s basement membrane and in the glomerular tuft.
To determine the effect of initiating ATRA in advanced disease, treatment was first initiated at week 5 in the group called ‘late-treatment’ rats. Compared to age-matched rats given normal sheep serum, the number of transitional cells lining Bowman’s basement membrane was not increased at week 16 in late-treatment PHN rats given DMSO (3.43 ± 0.36 vs. 3.00 ± 0.63/mm, normal sheep serum-injected rats, p > 0.05). In contrast, in the late-treatment group, ATRA significantly increased the number of transition cells in PHN rats at week 16 (6.08 ± 0.70 vs. 3.43 ± 0.36/mm, DMSO-treated PHN rats, p < 0.01) (fig. 2F-1). As expected, staining was absent when either primary antibody was omitted (fig. 2D-1 to D-4).
In the late-treatment PHN group, ATRA had no effect on the number of transition cells per square millimeter of glomerular tuft area at week 16 (p > 0.05 vs. late treatment with DMSO) (fig. 2F-2). These data show that when given late in the course of disease, ATRA increased the number of transition cells along Bowman’s basement membrane, but not within the glomerular tuft at the time point studied.
Prior to published descriptions of glomerular epithelial transitional cells, we reported that ATRA reduced podocyte proliferation in vitro and in vivo, defining podocytes by their anatomic position along the glomerular basement membrane (GBM) and the expression of synaptopodin . Thus, in order to study the effects of ATRA on the proliferation of glomerular epithelial cells along Bowman’s basement membrane, Ki-67 immunostaining was performed (fig. 3). The number of Ki-67-positive cells lining Bowman’s basement membrane was significantly increased in early DMSO-treated PHN rats at week 2 (4.3 ± 1.4 vs. 1.4 ± 0.3/mm Bowman’s basement membrane length, normal sheep serum-injected rats, p < 0.01). There was a statistically significant increase of proliferating cells along Bowman’s basement membrane in early-treatment ATRA PHN rats at week 2 (6.00 ± 0.90 vs. 4.30 ± 1.40, DMSO-treated PHN rats, p < 0.05) (fig. 3E). In contrast, compared to DMSO-treated PHN rats, there was no significant increase of Ki-67-positive cell number along Bowman’s basement membrane in ATRA-treated PHN rats either at week 5 in the early-treatment group (fig. 3E), or at week 16 in the late-treatment group (fig. 3F).
We have previously reported that podocyte number decreases in membranous (PHN) rats, occurring later in the course of disease . We therefore asked if the increase in glomerular transition cells by ATRA was associated with increased podocyte number, and the data are shown in figure 4. As expected, podocyte number was decreased at week 16 in late-treatment DMSO membranous rats (962 ± 55 vs. 1,431 ± 94/mm2 glomerular tuft area, age-matched normal sheep serum-injected rats, p < 0.01). However, ATRA significantly increased podocyte number at week 16 in late-treatment membranous rats (1,592 ± 85 vs. 962 ± 55/mm2, DMSO-treated PHN rats, p < 0.001).
Moreover, podocyte number in ATRA-treated animals at week 16 was similar in number to age-matched non-diseased controls (1,592 ± 85 vs. 1,431 ± 94/mm2, normal sheep serum-injected rats, p = 0.352). These data showed that when ATRA treatment was initiated in membranous rats after 3–4 weeks of disease, treatment for the next 10 weeks normalized podocyte number.
We have reported that ATRA significantly improves proteinuria in mice with experimental FSGS disease . In contrast, there was only a trend towards a lower protein/creatinine ratio in PHN rats treated with ATRA for 10 weeks (80.40 ± 70.40 vs. 219.95 ± 137.80, DMSO-treated PHN rats, p = 0.360), and no statistically significant decrease in protein/creatinine ratio compared to the day-5 time point, before the initiation of ATRA treatment (80.40 ± 70.40 vs. 186.15 ± 66.14, day-5 diseased rats, p = 0.453) (fig. 5). In order to better explain this, we examined nephrin and podocin staining. There was a segmental decrease in immunostaining for nephrin in 18.5% of glomeruli at week 16 in DMSO-treated PHN rats. This was reduced to 11% in the ATRA-treated animals (p < 0.05). Similarly, at week 16, 26.4% of glomeruli had a segmental decrease in podocin staining in PHN rats given DMSO, compared to 15.8% in ATRA-treated animals (p < 0.05).
The FSGS model in mice induced by the antiglomerular antibody was used as a second model, to test the hypothesis that ATRA increases the number of glomerular transition cells in disease. We have previously published data on podocyte number using this model . Double staining for PAX2 and WT-1 was used to measure the number of transition cells, and the results are shown in figure 6. There was only a trend towards an increase in the number of transition cells along Bowman’s basement membrane due to ATRA at week 1 (3.20 ± 0.60 vs. 2.04 ± 0.62 mm Bowman’s basement membrane length, DMSO-treated FSGS mice, p = 0.223). However, ATRA significantly increased the number of transition cells along Bowman’s basement membrane by week 2 (7.45 ± 0.83 vs. 1.26 ± 0.48/mm, DMSO-treated FSGS mice, p < 0.001) (fig. 6E). ATRA also increased the number of transition cells within the glomerular tuft at week 1 (44.06 ± 20.41 vs. 11.85 ± 11.85/mm2 glomerular tuft area, DMSO-treated FSGS mice p < 0.05), and at week 2 (48.80 ± 23.34 vs. 13.45 ± 13.45/mm2 glomerular tuft area, DMSO-treated FSGS mice, p < 0.05) (fig. 6F). These data show that ATRA increases the number of transition cells along Bowman’s basement membrane and within the glomerular tuft in experimental FSGS.
In order to study the effects of ATRA on the proliferation of glomerular epithelial cells along Bowman’s basement membrane in FSGS mice, Ki-67 immunostaining was performed (fig. 7). ATRA increased the number of Ki-67-positive cells along Bowman’s basement membrane at week 1 (4.82 ± 0.71 vs. 1.84 ± 0.41/mm, corn oil-treated FSGS mice, p < 0.05) and week 2 (5.67 ± 1.21 vs. 1.57 ± 0.40, corn oil-treated FSGS mice, p < 0.01). These results suggest that ATRA augments the proliferation of cells lining Bowman’s basement membrane in FSGS animals.
Studies have shown that podocytes do not have the cell cycle machinery necessary to adequately replace the decrease in cell number in many glomerular diseases, including membranous nephropathy and FSGS . The resultant decrease in podocyte number is a critical determinant and predictor for the development of proteinuria and progressive glomerulosclerosis . More recently, studies have shown the presence of glomerular cells that express both a podocyte and PEC proteins. These are commonly referred to as glomerular epithelial transition cells. Appel et al. [4,]Sagrinati et al. [5 ]and Ronconi et al.  have shown that their origin is likely PECs. A subset of these cells are likely progenitors for podocytes.
Although we have previously reported an increase in the number of glomerular epithelial transition cells (defined as cells in the glomerulus expressing both PEC- and podocyte-specific proteins) in PHN rats , the current study was designed to determine if ATRA could further augment this population of cells in disease. Indeed, when ATRA was first administered to membranous nephropathy rats (PHN model) immediately upon the detection of proteinuria, and regularly thereafter, the number of transition cells lining Bowman’s basement membrane and lining the GBM within the glomerular tuft were significantly increased compared to membranous rats given vehicle (DMSO). Early administration of ATRA resulted in an increase in staining for Ki-67 in cells lining Bowman’s capsule, consistent with an increase in proliferation.
Next, in order to better recapitulate the clinical setting of more advanced disease, membranous rats were first given ATRA late in the course of established disease (beginning at week 5), and regularly thereafter. The data showed that this late administration augmented the number of transition cells lining Bowman’s basement membrane, but not within the glomerular tuft. In contrast to the decrease in podocyte number at week 16 in membranous rats given vehicle, podocyte number was similar to age-matched healthy controls (given normal sheep serum) in membranous rats given ATRA at this time point.
To address whether these ATRA-associated changes are somehow unique to the PHN model or to rats, we examined archival tissue from our previously published study where ATRA administration improved proteinuria and increased podocyte number in mice with experimental FSGS . Our results show that ATRA also increased the number of transition cells lining Bowman’s basement membrane at the later time point week 2, and also along the GBM at both time points. Thus, these data show that in two models of reduced podocyte number, administering retinoids increased the number of glomerular epithelial transition cells, and improved podocyte number. This was accompanied by an increase in the number of proliferating PECs lining Bowman’s basement membrane in both models.
Despite a normalization of podocyte number in PHN, ATRA did not statistically improve proteinuria. This likely reflects the complex pathophysiology in this disease. For example, our data showed that although ATRA limited the decrease in levels for the slit-diaphragm protein nephrin and podocin in membranous rats, the decrease was still substantial compared to control. This and likely other pathways not affected by ATRA might explain the lack of effect on proteinuria. To our knowledge, no studies have correlated parietal transition cell number with the rescue of renal function. Moreover, the functional roles of parietal transition cells are not yet well delineated. Therefore, another interpretation might be that the degree to which parietal transition cell number increased following ATRA was still not sufficient, or could not fully transition into mature normal function podocytes lining the GBM.
Retinoids are derivatives of vitamin A. Their biological effects include inhibition of proliferation, induction of differentiation, cell survival and decreasing inflammation. Retinoids can also induce proliferation under certain circumstances . ATRA has been shown by our group and others to have several beneficial biological effects on the glomerulus during disease. Examples include acute and chronic models of mesangioproliferative glomerulonephritis, where retinoids improved renal function, decreased albuminuria, and reduced glomerular damage [12,13,14,15,16,19,24]. In puromycin aminonucleoside-induced nephrosis, retinoids reduced proteinuria by protecting podocytes from injury . Isotretinoin significantly reduces glomerular damage in rats with chronic glomerulonephritis . The protective effects of retinoids have also been reported in mice with diabetic nephropathy , in antibody-mediated podocyte injury  and in experimental HIVAN [12,13]. We showed that ATRA augments staining for nephrin, podocin, and synaptopodin in podocytes .
To our knowledge, this is the first in vivo study to report that ATRA increases the proliferation of PECs and the number of glomerular epithelial transition cells, defined as cells expressing both a podocyte and a PEC protein, on Bowman’s basement membrane. This is in contrast to the reported decreased proliferation and differentiation that ATRA induces in injured podocytes on the GBM [3,12]. Intriguingly, Ronconi et al. [6 ]used retinoids in the culture medium to differentiate PEC progenitor cells towards the podocyte lineage. Taken together, these findings suggest that retinoids may serve as a trophic mitogen versus growth arrest and differentiation factor for glomerular epithelial cells that depend on the distinct molecular pathways governing their state of lineage commitment and anatomic location in the glomerulus . Indeed, the recent discovery that cell-cycle controls are unique in PECs as compared to podocytes supports this notion .
The precise mechanism underlying how ATRA might induce PECs to begin to express a protein once considered unique to podocytes is unknown. Retinoids have been shown to regulate many signaling pathways affecting cell proliferation, differentiation, reproduction, and maintenance of normal tissues, especially epithelial cells . Based on studies that we and others have undertaken on ATRA’s effects on podocyte differentiation and proliferation [3,10,12], future considerations should be directed at nuclear retinoic acid receptors and retinoic acid response elements , cyclin-dependent kinase inhibitors [29,30], signaling pathways including cAMP/protein kinase A pathway, MAPK1,2 and Stat3 phosphorylation , and the p38 MAPK pathway . As noted above, however, ATRA may interact with molecular pathways in PECs that do not overlap with those in podocytes.
In summary, the results of the current study show that giving retinoids to animals with experimental glomerular disease resembling membranous nephropathy and FSGS increases the number of glomerular epithelial transition cells and podocytes.
These studies were supported by grants from the National Institutes of Health R01DK056799, R21DK081835 (S.J.S.). This work has been made possible also through J. Zhang’s International Society of Nephrology-funded fellowship.
No conflicts of interest are declared by the authors.
Stuart J. Shankland
Department of Medicine, Division of Nephrology
University of Washington School of Medicine, Box 356521
BB-1265 H.S.B., 1959 NE Pacific Street, Seattle, WA 98195-6521 (USA)
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.